Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 5:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–263 of 263 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Nebulizer Clear all
Completed Phase 3 Interventional Results available

A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD

NCT02276222
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
SUN-101 50 mcg BID eFlow (CS) nebulizer, Spiriva® 18 mcg QD Handihaler
Drug
Lead sponsor
Sunovion Respiratory Development Inc.
Industry
Eligibility
40 Years and older
Enrollment
1,087 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
83
States / cities
Andalusia, Alabama • Birmingham, Alabama • Jasper, Alabama + 68 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 23, 2026, 5:40 PM EDT
Completed Not applicable Interventional

Saline Hypertonic in Preschoolers

NCT02378467
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
7% Hypertonic Saline (HS), 0.9% Isotonic Saline (IS)
Drug
Lead sponsor
University of Washington, the Collaborative Health Studies Coordinating Center
Other
Eligibility
3 Years to 5 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
23
States / cities
Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 23, 2026, 5:40 PM EDT
Completed Phase 1 Interventional

Nebulized Inhaled Milrinone in a Hospitalized Advanced Heart Failure Population

NCT02077010
View directory record Official record
Conditions
Heart Failure, Cardiomyopathy
Interventions
Inhaled nebulized milrinone
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Kansas City, Kansas • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 23, 2026, 5:40 PM EDT
Completed Phase 4 Interventional

Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension

NCT00403650
View directory record Official record
Conditions
Sarcoidosis, Pulmonary Arterial Hypertension
Interventions
Iloprost
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 12, 2013 · Synced Oct 23, 2026, 5:40 PM EDT
Completed Phase 3 Interventional Results available

Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa

NCT00757237
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Aztreonam for Inhalation Solution (AZLI), Tobramycin Inhalation Solution (TIS)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
29
States / cities
Anchorage, Alaska • Phoenix, Arizona • Tuscon, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2011 · Synced Oct 23, 2026, 5:40 PM EDT
Completed No phase listed Observational

Investigate the Aerosol Particle Distribution During Aerosol Generating Procedures

NCT04353531
View directory record Official record
Conditions
Transmission, Patient Professional, High-flow Nasal Cannula
Interventions
High-flow nasal cannula, Surgical mask, bronchoscopy examination, intubation, tracheostomy, nebulization, Pulmonary function test
Device · Procedure · Diagnostic Test
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Oct 23, 2026, 5:40 PM EDT
Completed Not applicable Interventional Results available

Aerosolized Albuterol Use in Severe BPD

NCT02766673
View directory record Official record
Conditions
Severe Bronchopulmonary Dysplasia
Interventions
Albuterol Sulfate, Sterile Saline
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 1 Year
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 23, 2026, 5:40 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF

NCT06237335
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
RCT2100, Placebo, Ivacaftor
Drug · Other
Lead sponsor
ReCode Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
13
States / cities
Birmingham, Alabama • Tucson, Arizona • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 23, 2026, 5:40 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Effects of Bevespi on Ventilation and Gas Exchange Abnormalities in COPD Assessed by 129Xe MRI

NCT03324607
View directory record Official record
Conditions
COPD
Interventions
hyperpolarized 129Xe gas MRI, Bevespi Aerosphere
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
40 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 23, 2026, 5:40 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE

NCT02630316
View directory record Official record
Conditions
Pulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and Emphysema
Interventions
Inhaled Treprostinil, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
96
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Oct 23, 2026, 5:40 PM EDT
Completed Phase 2 Interventional Results available

Aztreonam Lysine for Pseudomonas Infection Eradication Study

NCT01375049
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Aztreonam for Inhalation Solution (AZLI)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
3 Months to 17 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
23
States / cities
Phoenix, Arizona • Jacksonville, Florida • Orlando, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2014 · Synced Oct 23, 2026, 5:40 PM EDT
Terminated Phase 4 Interventional Results available

Comparison of Nebulizers in ED in Pediatric Asthma Patients

NCT01951378
View directory record Official record
Conditions
Asthma
Interventions
Hudson RCI® nebulizer, NebuTech® HDN® nebulizer, Albuterol
Device · Drug
Lead sponsor
Seton Healthcare Family
Other
Eligibility
3 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 23, 2026, 5:40 PM EDT
Completed Phase 3 Interventional

Nebulizer Intervention for Minority Children With Asthma

NCT00218816
View directory record Official record
Conditions
Asthma
Interventions
Nebulizer Education Intervention, Standard Asthma Education Groups
Behavioral
Lead sponsor
National Institute of Nursing Research (NINR)
NIH
Eligibility
2 Years to 8 Years
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 5, 2008 · Synced Oct 23, 2026, 5:40 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Drug Study of Albuterol to Treat Acute Lung Injury

NCT00434993
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Albuterol Sulfate, Mini-Bronchoalveolar Lavage (BAL), Placebo
Drug · Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
13 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
40
States / cities
Fresno, California • Sacramento, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 23, 2026, 5:40 PM EDT
Completed Phase 3 Interventional Results available

Safety of Tobramycin Inhalation Powder (TIP) vs Tobramycin Solution for Inhalation in Patients With Cystic Fibrosis

NCT00388505
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Tobramycin Inhalation Powder, Tobramycin Solution for Inhalation
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years and older
Enrollment
517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
24
States / cities
Hartford, Connecticut • Atlanta, Georgia • Chicago, Illinois + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2012 · Synced Oct 23, 2026, 5:40 PM EDT
Recruiting Phase 1 Interventional

Nebulized Human Amniotic Fluid in Patients With Interstitial Lung Disease

NCT07372989
View directory record Official record
Conditions
Lung Diseases, Interstitial
Interventions
Matrix
Biological
Lead sponsor
Maule Stem Cell Research Institute, Inc.
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Venice, Florida
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 5:40 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Nebulized Hypertonic Saline for Mechanically Ventilated Children

NCT01945944
View directory record Official record
Conditions
Respiratory Failure
Interventions
Hypertonic saline (3%), Placebo (0.9% saline)
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
Up to 18 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 28, 2016 · Synced Oct 23, 2026, 5:40 PM EDT
Completed Phase 2 Interventional Results available

A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD

NCT02038829
View directory record Official record
Conditions
COPD
Interventions
Placebo, SUN101 3 mcg, SUN-101 6.25 mcg, SUN-101 12.5 mcg, SUN-101 50 mcg, Aclidinium
Drug
Lead sponsor
Sunovion Respiratory Development Inc.
Industry
Eligibility
40 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
10
States / cities
Clearwater, Florida • Charlotte, North Carolina • Raleigh, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2018 · Synced Oct 23, 2026, 5:40 PM EDT
No Longer Available No phase listed Expanded access

Cyclosporine Inhalation Solution (CIS) in Lung Transplant Recipients

NCT00633373
View directory record Official record
Conditions
Lung Transplant
Interventions
Cyclosporine Inhalation Solution
Drug
Lead sponsor
APT Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
U.S. locations
8
States / cities
San Francisco, California • Gainesville, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2012 · Synced Oct 23, 2026, 5:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration

NCT02679729
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
AZD5634 for inhalation, AZD5634 for infusion, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 5, 2018 · Synced Oct 23, 2026, 5:40 PM EDT
Withdrawn Phase 2 Interventional

BIO-11006 for Osteosarcoma and Ewing's Sarcoma Lung Metastases

NCT04183062
View directory record Official record
Conditions
Osteosarcoma Metastatic, Ewing's Sarcoma Metastatic
Interventions
Chemotherapy (gemcitabine & docetaxel) plus BIO-11006
Drug
Lead sponsor
Nicklaus Children's Hospital f/k/a Miami Children's Hospital
Other
Eligibility
5 Years to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 8, 2024 · Synced Oct 23, 2026, 5:40 PM EDT
Completed Phase 4 Interventional Results available

Nebulized Sub-dissociative Dose Ketamine at Three Different Dosing Regimens for Treating Acute Pain in the Pediatric ED

NCT03950817
View directory record Official record
Conditions
Pain
Interventions
Nebulized Sub-dissociative Dose Ketamine at either 0.75 mg/kg, Nebulized Sub-dissociative Dose Ketamine at 1 mg/kg, Nebulized Sub-dissociative Dose Ketamine at 1.5 mg/kg.
Drug
Lead sponsor
Antonios Likourezos
Other
Eligibility
7 Years to 17 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 23, 2026, 5:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Feasibility of a Mobile Medication Plan Application in CF Patient Care

NCT03637504
View directory record Official record
Conditions
Cystic Fibrosis, Cystic Fibrosis in Children
Interventions
MedActionPlan®
Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
12 Years and older
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
5
States / cities
Birmingham, Alabama • Tucson, Arizona • Stanford, California + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 23, 2026, 5:40 PM EDT